Com­pany News

BioSpectrum (Asia) - - Bio Content -

My­lan, one of the world’s lead­ing phar­ma­ceu­ti­cal com­pa­nies, and Mapi Pharma Ltd., a fully in­te­grated, clinical late stage bio­phar­ma­ceu­ti­cal com­pany from Is­rael, have an­nounced that the two com­pa­nies will part­ner on the devel­op­ment and com­mer­cial­iza­tion of GA De­pot, a long-act­ing Glati­ramer Ac­etate prod­uct. My­lan is ac­quir­ing global mar­ket­ing rights to the prod­uct. GA De­pot is a pro­posed once-monthly in­jec­tion for the treat­ment of pa­tients with re­laps­in­gremit­ting mul­ti­ple scle­ro­sis, or RRMS. Mul­ti­ple scle­ro­sis (MS) or­ga­ni­za­tions have es­ti­mated that 2.3 mil­lion in­di­vid­u­als are liv­ing with MS world­wide. In the US, pre­lim­i­nary re­sults of an MS preva­lence study by the Na­tional MS So­ci­ety es­ti­mate that nearly 1 mil­lion peo­ple are liv­ing with MS. Re­laps­ing-re­mit­ting MS ac­counts for ap­prox­i­mately 85 per cent of ini­tial MS di­ag­noses. Mapi Pharma has strong re­search ca­pa­bil­i­ties in the devel­op­ment of long-act­ing de­pot in­jec­tions. My­lan brings to this col­lab­o­ra­tion its reg­u­la­tory ex­per­tise, unique global com­mer­cial plat­form and sig­nif­i­cant ex­pe­ri­ence in launch­ing other Glati­ramer Ac­etate in­jec­tion prod­ucts.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.